VTRS Stock Chart & Stats
$276.02
$0.00(0.00%)
At close: 4:00 PM EDT
$276.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$150.00 - $332.79
Previous CloseN/A
Volume0.00
Average Volume (3M)2.37K
Market Cap
$372.35B
Enterprise Value$30.69K
Total Cash (Recent Filing)$1.51B
Total Debt (Recent Filing)$13.63B
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Nov 09, 2026EPS Estimate
11.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding1,148,590,800
10 Day Avg. Volume2
30 Day Avg. Volume2,374
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.99
Price to Sales (P/S)1.02
P/FCF Ratio7.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$351.55Price Target Upside27.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)45.27
Revenue Forecast (FY)$265.93B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationRobust operating and free cash flow despite reported net losses indicates meaningful underlying cash earnings and working-capital discipline. This supports debt repayment, shareholder returns, pipeline investment, and financial flexibility over the next several quarters.
Raised Operating OutlookRaising full-year targets after a quarterly revenue, EBITDA, and EPS beat signals improved execution and management confidence. Expected growth across revenue and earnings can reinforce operating momentum and provide a stronger base for continued margin improvement.
Pipeline And Complex-product ExpansionRegulatory progress and a high approval cadence can broaden Viatris’s portfolio beyond highly commoditized generics. Complex products, biosimilars, and newly approved medicines may improve differentiation, support future launches, and diversify revenue sources.
Bears Say
Persistent Unprofitable EarningsNegative operating profit and net income weaken the quality and consistency of shareholder returns, even with strong cash generation. Historical swings from profitability to losses and declining gross margin raise questions about the durability of earnings and cost recovery.
Nashik Supply DisruptionThe Nashik fire and subsequent FDA inspection observations create a material execution and supply risk during the coming reporting periods. Lost sales in lower-margin generics still pressure scale, customer continuity, and the company’s ability to deliver its updated outlook.
China Procurement ExposureGreater China has been a major growth contributor, so provincial implementation of procurement changes could weaken hospital-channel volumes and reduce the pace of expansion. This adds uncertainty to regional growth and may pressure product mix and revenue planning.
Viatris News
VTRS FAQ
What was Viatris’s price range in the past 12 months?
Viatris lowest stock price was $150.00 and its highest was $332.79 in the past 12 months.
What is Viatris’s market cap?
Viatris’s market cap is $372.35B.
When is Viatris’s upcoming earnings report date?
Viatris’s upcoming earnings report date is Nov 09, 2026 which is in 37 days.
How were Viatris’s earnings last quarter?
Viatris released its earnings results on Aug 06, 2026. The company reported $12.623 earnings per share for the quarter, beating the consensus estimate of $10.995 by $1.628.
Is Viatris overvalued?
According to Wall Street analysts Viatris’s price is currently Undervalued.
Does Viatris pay dividends?
Viatris does not currently pay dividends.
What is Viatris’s EPS estimate?
Viatris’s EPS estimate is 11.8.
How many shares outstanding does Viatris have?
Viatris has 1,148,590,800 shares outstanding.
What happened to Viatris’s price movement after its last earnings report?
Viatris reported an EPS of $12.623 in its last earnings report, beating expectations of $10.995. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Viatris?
Currently, no hedge funds are holding shares in MX:VTRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viatris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$351.55 (27.37% Upside)
$351.55 (27.37% Upside)
Blogger Sentiment
Bullish
MX:VTRS Sentiment 60%
Sector Average 65%
Sector Average 65%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
79.18%
12-Months-Change
Fundamentals
Return on Equity
2.69%
Trailing 12-Months
Asset Growth
-8.77%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Viatris
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
VTRS Company Deck
VTRS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive operational and strategic momentum: the company beat expectations in Q2 on revenue, EBITDA and EPS, raised full-year guidance across key metrics, showed margin improvement, strong cash generation, aggressive capital returns, meaningful pipeline and regulatory progress (Gwyn Lo approval, Nefecon topline, Phase III programs on track). Offsetting this, notable near-term challenges include Nashik manufacturing disruptions (with a $100–$150 million H2 revenue headwind), emerging markets supply constraints, competitive pressure in some developed-market products, and China procurement policy uncertainty that may moderate future growth. Overall, management framed the challenges as mostly short-term and fully considered in the updated guidance while emphasizing long-term growth opportunities and financial flexibility.View all MX:VTRS earnings summariesVTRS Net sales Breakdown
64.45% Brands
35.55% Generics
VTRS Stock 12 Month Forecast
Average Price Target
$351.55
▲(27.37% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Perrigo Company
―
Teva
―
Amneal Pharmaceuticals
―
Alvotech
―